Eli Lilly and Company (NYSE:LLY) Posts Earnings Results

Eli Lilly and Company (NYSE:LLY) released its quarterly earnings results on Wednesday. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.06 by $2.32, FiscalAI reports. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.69 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm earned $6.31 EPS. Eli Lilly and Company updated its FY 2026 guidance to 35.500-36.500 EPS.

Here are the key takeaways from Eli Lilly and Company’s conference call:

• Q2 revenue rose 48% year over year to $6.8 billion of incremental growth from key products, led by Mounjaro and Zepbound; non-GAAP EPS increased to $8.38 from $6.31.
• Lilly raised its 2026 outlook, increasing the revenue range to $85 billion-$87 billion and non-GAAP EPS guidance to $35.50-$36.50, reflecting stronger-than-expected first-half performance.
• Foundayo’s launch is gaining traction as access expands through major PBMs and the Medicare GLP-1 Bridge program; Lilly reported recent prescription acceleration, 36,000 U.S. prescribers, and encouraging initial international demand.
• The pipeline produced several important advances, including positive phase III retatrutide results, an FDA submission for orforglipron in diabetes, strong oncology data for pirtobrutinib and selpercatinib, and regulatory progress for weekly insulin efsitora alfa.
• U.S. net pricing declined, with reported price down 3% and an underlying decline of approximately 9% excluding rebate and discount adjustments; management also cautioned that prior-period adjustments and seasonal factors will affect second-half comparisons.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded up $54.62 during mid-day trading on Wednesday, hitting $1,170.30. The company’s stock had a trading volume of 6,433,137 shares, compared to its average volume of 2,440,108. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The stock’s fifty day moving average price is $1,156.45 and its two-hundred day moving average price is $1,045.49. The stock has a market capitalization of $1.10 trillion, a P/E ratio of 41.57, a P/E/G ratio of 1.39 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat: Revenue rose 48% year over year to $22.97 billion, surpassing the approximately $20.7 billion consensus estimate. Non-GAAP EPS was $8.38 versus expectations of about $6.06, while reported EPS was $7.94. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: GLP-1 demand drove growth: Mounjaro and Zepbound sales surged, with Mounjaro reportedly up 91% and the two products generating nearly two-thirds of quarterly revenue. Continued volume growth in diabetes and obesity treatments was the primary catalyst for the stock’s advance. Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%
• Positive Sentiment: Outlook raised: Lilly increased 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and maintained EPS guidance of $35.50-$36.50. The improved outlook indicates management expects momentum to continue. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
• Positive Sentiment: Additional commercial and pipeline support: CVS Health expanded its weight-management program through a Lilly partnership, while Lilly is widening early access to experimental obesity drug retatrutide. The FDA also granted breakthrough therapy designation to investigational cancer drug olomorasib, adding longer-term pipeline potential.
• Neutral Sentiment: Key investor concern: Management indicated that manufacturing capacity could become a bottleneck if GLP-1 demand continues to outpace supply. Lilly is working to expand production, but execution and competition remain important risks at the stock’s elevated valuation.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently modified their holdings of LLY. Mcguire Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $38,000. Gilpin Wealth Management LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $54,000. Turning Point Benefit Group Inc. acquired a new stake in Eli Lilly and Company during the 3rd quarter worth about $56,000. Vermillion & White Wealth Management Group LLC lifted its stake in Eli Lilly and Company by 57.1% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 55 shares of the company’s stock valued at $59,000 after buying an additional 20 shares in the last quarter. Finally, Graney & King LLC boosted its holdings in shares of Eli Lilly and Company by 14.6% in the second quarter. Graney & King LLC now owns 181 shares of the company’s stock worth $141,000 after buying an additional 23 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LLY. UBS Group boosted their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Truist Financial increased their price target on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Leerink Partners lifted their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Finally, Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,283.64.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.